NCT06262581View on ClinicalTrials.gov

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

September 23, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2025

Conditions

DMMR Colorectal CancerAnti PD-1Immunotherapy

Interventions

DRUG

Tisleizumab(BGB-A317)

200mg i.v. q3w

Trial Locations (1)

510060

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER